A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma

Por Benson, Don M., Cohen, Adam D., Jagannath, Sundar, Munshi, Nikhil C., Spitzer, Gary, Hofmeister, Craig C., Efebera, Yvonne A., Andre, Pascale, Zerbib, Robert, Caligiuri, Michael A.
Publicado no Clin Cancer Res (2015)

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Por Matasar, Matthew J., Czuczman, Myron S., Rodriguez, Maria Alma, Fennessy, Michael, Shea, Thomas C., Spitzer, Gary, Lossos, Izidore S., Kharfan-Dabaja, Mohamed A., Joyce, Robin, Fayad, Luis, Henkel, Kristen, Liao, Qiming, Edvardsen, Klaus, Jewell, Roxanne C., Fecteau, Doug, Singh, Rajendra P., Lisby, Steen, Moskowitz, Craig H.
Publicado em 2013